Fig. 2

Changes in plasma levels of sIL-2Rα and IL-2 in AIS patients and their correlation with neurological deficits. a Plasma level of sIL-2Rα detected by ProcartaPlex in AIS patients and control subjects. b Plasma level of sIL-2Rα in AIS patients with favourable (mRS score = 0–2) and unfavourable (mRS score = 3–6) functional outcomes. c–e Correlation of admission NIHSS score, 3-month mRS score and lymphocyte/neutrophil ratio with the plasma level of sIL-2Rα. f Plasma levels of IL-2 detected by ProcartaPlex in AIS patients and control subjects. g Plasma levels of IL-2 in AIS patients with favourable (mRS score = 0–2) and unfavourable (mRS score = 3–6) functional outcomes. h–j Correlation of admission NIHSS score, 3-month mRS score and lymphocyte/neutrophil ratio with the plasma level of IL-2; N = 76 for controls, N = 201 for AIS patients (N = 128 for the favourable outcome group, N = 73 for the unfavourable outcome group). ****p < 0.0001, ***p < 0.001, *p < 0.05. AIS, acute ischaemic stroke; sIL-2Rα, soluble interleukin-2 receptor α; IL-2, interleukin-2; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale